Using blood markers to improve treatment for metastatic pancreatic cancer
Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer
Beneficência Portuguesa de São Paulo · NCT06945978
This study is testing if analyzing certain blood markers can help doctors better tailor treatments for patients with advanced pancreatic cancer starting a specific chemotherapy regimen.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Beneficência Portuguesa de São Paulo (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (São Paulo, São Paulo) |
| Trial ID | NCT06945978 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the understanding of pancreatic cancer treatment response by analyzing small molecules called miRNAs in the blood of patients with metastatic pancreatic ductal adenocarcinoma (PDAC). The research focuses on patients starting treatment with the FOLFIRINOX regimen, utilizing liquid biopsy techniques to collect blood samples for miRNA analysis. By identifying specific miRNA expression patterns, the study seeks to predict treatment effectiveness and enable personalized therapeutic adjustments, ultimately improving patient outcomes. The approach combines cost-effective qPCR methods with innovative liquid biopsy technology to facilitate early detection of treatment responses and disease progression.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with metastatic pancreatic ductal adenocarcinoma and are about to begin treatment with FOLFIRINOX.
Not a fit: Patients who have previously undergone chemotherapy or do not meet the criteria for the proposed treatment regimen may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with metastatic pancreatic cancer.
How similar studies have performed: While the approach of using miRNA biomarkers in cancer treatment monitoring is gaining traction, this specific application in metastatic pancreatic cancer is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients diagnosed with metastatic PDAC; * Patients who will start treatment with FOLFIRINOX; * 18 years or older; * Who agree to participate in the study by signing the Informed Consent Form; Exclusion Criteria: * Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment; * Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;
Where this trial is running
São Paulo, São Paulo
- A Beneficência Portuguesa de São Paulo — São Paulo, São Paulo, Brazil (RECRUITING)
Study contacts
- Study coordinator: Camila Farias
- Email: camila.farias@bp.org.br
- Phone: +551135054680
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreatic Cancer, Metastasis, Epigenetic, Pancreatic cancer, miRNA, Treatment response, Folfirinox